Genistein

Phase 2Small molecule

NNational Cancer Institute (NCI)

Genistein is one of 65 small molecule programs targeting Cardiomyopathy. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CardiomyopathyRecruiting

Heart FailureRecruiting

CardiomyopathyPhase 2

Recruiting

Heart FailurePhase 2

Recruiting

Competition

Competitive Landscape

206 competitors in Heart Failure

#DrugCompanyPhaseTrials

Bayer Aspirin

Bayer

Preclinical

2 2

Brethine

Sanofi

Preclinical

1 3

Medrol

Pfizer

Preclinical

1 4

Amidate

Pfizer

Preclinical

1 5

Activase

Zemplar

Adriamycin

Savaysa

Xifaxan

2 10

Genistein

NNational Cancer Institute (NCI)

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Not yet recruiting

Obesity

NCT07033767

Clinical

Trials by Indication[1]

Prostate Cancer3 trials

Synthetic Genistein (BONISTEIN™) in Patients Who Are Undergoing Surgery for Prostate Cancer

Unknown status·UUniversity Hospital, Aker·Phase 2·NCT00546039·47 enrolled

Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer

Terminated·EEmory University·Phase 2·NCT02766478·10 enrolled

Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01325311·15 enrolled

Bladder Cancer2 trials

Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment

Completed·EEmory University·Phase 2·NCT01489813·36 enrolled

Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00118040·60 enrolled

Tyrosine Kinase Inhibitor1 trial

A Pharmacokinetic Study of Genistein, a Tyrosine Kinase Inhibitor

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00001696·15 enrolled

Cystic Fibrosis1 trial

Phenylbutyrate/Genistein Duotherapy in Delta F508-Heterozygotes (for Cystic Fibrosis)

Terminated·—·Phase 1/2·NCT00590538·9 enrolled

Coronary Artery Disease1 trial

Isoflavones and the Coronary Circulation in Men and Women With Coronary Artery Disease

Completed·IImperial College London·Phase 2/3·NCT00287690·71 enrolled

8 more indications

Estrogen1 trial

CVD Risk and Health in Postmenopausal Phytoestrogen Users

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00000613

Heart Failure1 trial

Cardiovascular Genistein Therapy for Heart Failure Inflammation

Recruiting·UUniversity Medical Centre Ljubljana·Phase 1/2·NCT06501768·40 enrolled

Metastatic Colorectal Cancer1 trial

Genistein in Treatment of Metastatic Colorectal Cancer

Completed·SSofya Pintova·Phase 1/2·NCT01985763·13 enrolled

Oncology Patients1 trial

Study of Genistein in Pediatric Oncology Patients (UVA-Gen001)

Terminated·UUniversity of Virginia·Phase 2·NCT02624388·4 enrolled

Postmenopausal Women1 trial

Vascular and Skeletal Protective Effects of Genistein in Postmenopausal Women

Completed·UUniversity of Messina·Phase 2/3·NCT00355953·400 enrolled

Cardiomyopathy1 trial

Genistein in trAnSthyretin recePtor Amyloid caRdiomyopathy

Recruiting·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·Phase 1/2·NCT06634108·20 enrolled

Breast Cancer1 trial

Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00290758·126 enrolled

Obesity1 trial

Exploring a Natural Solution for Childhood Obesity

Not yet recruiting·WWestern University·Phase 1/2·NCT07033767·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Genistein. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Genistein compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Genistein. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Cancer Institute (NCI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Cancer Institute (NCI)

Genistein

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Prostate Cancer3 trials

Bladder Cancer2 trials

Tyrosine Kinase Inhibitor1 trial

Cystic Fibrosis1 trial

Coronary Artery Disease1 trial

Estrogen1 trial

Heart Failure1 trial

Metastatic Colorectal Cancer1 trial

Oncology Patients1 trial

Postmenopausal Women1 trial

Cardiomyopathy1 trial

Breast Cancer1 trial

Obesity1 trial

References

Drug Info

Quick Facts

Related News